Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 11/20 | 0.58 |
| ▸ | PREP | P48147 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706517 | 1.00 | FKBP1A (0.58) | FKBP1APREPNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8773327 | 1.00 | FKBP1A (0.58) | FKBP1APREPNPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1784260 | 0.99 | FKBP1A (0.57) | FKBP1APREPNPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9251636 | 0.99 | FKBP1A (0.57) | FKBP1APREPNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28351585 | 0.84 | FKBP1A (0.67) | FKBP1APREP | |
| SCHEMBL13148433 | 0.84 | FKBP1A (0.57) | FKBP1APREPSMN1; SMN2 | |
| SCHEMBL13413549 | 0.84 | FKBP1A (0.57) | FKBP1APREPSMN1; SMN2 | |
| SCHEMBL13099455 | 0.84 | FKBP1A (0.60) | FKBP1APREP | |
| SCHEMBL27553714 | 0.84 | FKBP1A (0.57) | FKBP1APREPNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12869918 | 0.84 | FKBP1A (0.60) | FKBP1APREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109414402-B | Method for preparing a drug delivery system with a testosterone compound present externally or topically and such a drug delivery system | EB IP希博里塔布斯有限责任公司 | 2022-11-04 | — | — | CN | disclosed |
| US-9683002-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9670186-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9487514-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-11-08 | — | — | US | disclosed |
| US-9447148-B2 | Melanocortin-1 receptor-specific cyclic peptides | PALATIN TECHNOLOGIES, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160090393-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160083372-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-24 | — | — | US | disclosed |
| US-9181206-B2 | Dual-acting oxazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150158819-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-06-11 | — | — | US | disclosed |
| US-9045443-B2 | Nitric oxide donor neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-8173840-B2 | Compounds with high therapeutic index | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2007089745-A2 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | SIGNATURE R & D HOLDINGS, LLC (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20060241017-A1 | Novel compounds with high therapeutic index | SIGNATURE R&D HOLDINGS, LLC | 2006-10-26 | — | — | US | disclosed |
| EP-1134213-B1 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-0832065-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1134213-A2 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER INC. (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6277877-B1 | GLYCOGEN PHOSPHORYLASE INHIBITOR; ANTIDIABETIC AGENTS | PFIZER, INC. | 2001-08-21 | — | — | US | disclosed |
| US-6107329-A | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | PFIZER, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| EP-0544620-A1 | Macrocyclic lactams as inhibitors of atrial natriuretic factors (ANF)-degrading neutral endopeptidase (NEP) | CIBA-GEIGY AG (CH) | 1993-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090393-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FKBP1A 2960/4885PREP 11/4885NPC1 312/4885 |
| US-20160083372-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FKBP1A 3044/4885PREP 9/4885NPC1 476/4885 |
| US-20150158819-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FKBP1A 3449/4885PREP 12/4885NPC1 186/4885 |
| US-20060241017-A1 | Novel compounds with high therapeutic index | IL4I1, SLC7A1, GOT1 | FKBP1A 777/4885PREP 659/4885NPC1 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.